Clinical Trials

Clinical trials are research studies that test whether new medical treatments, devices or strategies  are safe and effective.

People who volunteer for clinical trials play an active role in their own health care, often gain access to experimental treatments, and help others by improving and advancing medical care.

At Providence Cancer Center, our scientists and physicians work closely together to make clinical trials a regular part of cancer care. Patients may take part in studies initiated by our translational researchers at the Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute, in addition to studies sponsored by the National Cancer Institute or pharmaceutical and biotechnology companies.

Our clinical trials team works directly with physicians to identify clinical trials appropriate for their patients’ specific stage of disease.

The goals of clinical research vary from trial to trial. Generally, they are designed to:

  • Improve prevention, early diagnosis and treatment of cancer
  • Discover whether a particular drug  or medical treatment is safe and effective
  • Advance the state of scientific and medical knowledge
  • Measure and improve the quality of life for patients and their families
Find cancer clinical trials available in Oregon in the list below. You may search by keyword or condition/disease, or browse using the page numbers and arrows. Find additional trials by using the search term “Oncology Multiple Tumor Sites". To learn more about a particular trial and qualification criteria, click the trial name and then the listed contact link, or talk with your physician.

For more information about clinical trials available through Providence Cancer Center, call 503-215-2614
« Previous 12345 Next »
Viewing Page 1 of 29 | Showing Results 1 - 5 of 142

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

This randomized phase II/III trial studies how well temozolomide and veliparib work and compare them to temozolomide alone in treating patients...

Keith Lanier MD
  • Clackamas Radiation Oncology Center
  • Oncology and Hematology Care Southeast
  • Providence Newberg Medical Center
  • Providence Portland Medical Center
  • Providence St. Vincent Medical Center
  • Providence Willamette Falls Medical Center

A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, Alliance IND #15380) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)

This randomized phase II trial studies how well giving vaccine therapy with or without bevacizumab works in treating patients with recurrent...

Keith Lanier MD
  • California Research
  • Clackamas Radiation Oncology Center
  • Oncology and Hematology Care Southeast
  • Providence Newberg Medical Center
  • Providence Portland Medical Center
  • Providence St. Vincent Medical Center
  • Providence Willamette Falls Medical Center

A Phase III randomized double-blind, controlled study of ICT-107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy

ICT-107 consists of dendritic cells, prepared from autologous mononuclear cells that are pulsed with six synthetic peptides that were derived from...

Marka Crittenden MD PhD
  • Oncology and Hematology Care Eastside

A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases

This randomized phase III trial compares memantine hydrochloride and whole-brain radiotherapy with or without hippocampal avoidance in reducing...

Keith Lanier MD
  • Clackamas Radiation Oncology Center
  • Oncology and Hematology Care Southeast
  • Providence Newberg Medical Center
  • Providence Portland Medical Center
  • Providence St. Vincent Medical Center
  • Providence Willamette Falls Medical Center

Phase I Study of Safety and Immunogenicity of ADU-623, a live-attenuated Listeria monocytogenes vaccine (ΔactA/ΔinlB) expressing EGFRvIII and NY-ESO-1, in Patients with Treated and Recurrent WHO Grade III/IV Astrocytomas

This is a study for patients with brain tumors called astrocytic tumors. The study will enroll patients who have received standard treatment. The...

Marka Crittenden MD PhD
  • Oncology and Hematology Care Eastside
  • Providence Portland Medical Center
« Previous 12345 Next »
Viewing Page 1 of 29 | Showing Results 1 - 5 of 142